CONSULTANT HAEMATOLOGIST
Dr Paul Turner
MBBS FRACP FRCPA
Dr Paul Turner graduated from Melbourne University in 1991 and has been working as a
consultant haematologist since 2001 after training in this field at the Alfred and Austin hospitals in Melbourne. He has worked in bone marrow transplantation, malignant haematology and general haematology with both clinical and laboratory components. His current public hospital appointment (since 2018) is at Northern Health and his main private hospital is John Fawkner at Coburg.
His private practice involves all areas of haematology including providing chemotherapy,
thrombosis and haemostasis, blood product and iron transfusions via John Fawkner Hospital.
Dr Turner also works as a laboratory haematologist at Dorevitch pathology.
Although a specialist with wide-ranging expertise Dr Turner has a special interest in Chronic Lymphocytic Leukaemia (CLL), with involvement in clinical trials in this area in both the private and public sectors. Other special interests are Myeloproliferative disorders and autologous stem cell transplantation.
He is a member of the Australia and New Zealand Leukaemia-Lymphoma group (ALLG) and a fellow of the RCPA and RACP.
Practice Interests
Dr Paul Turner is an experienced general haematologist with a special interest in malignant haematology.
His clinical approach ensures he spends time to build up rapport and listen to the patient’s concerns as well as utilising his expertise in haematologic pathologic diagnosis to ensure good outcomes.
Practice Locations
Dr Turner consults privately in his rooms located in Coburg.
TeleHealth appointments are available.
265 Moreland Road
Coburg VIC 3058
Tel: 03 9386 5527
Fax: 03 9383 7185
Hospital Accreditation
Clinical Interests Include:
Extended Profile
Dr Paul Turner
– Key Research, Journal & Book Publications, Presentations &/or Awards
Professional Memberships
Australasian Leukaemia and Lymphoma Group
Fellow of the Royal College of Pathologists of Australia (FRCPA)
Fellow of Royal Australasian College of Physicians (FRACP)
Selected Journal Publications
Involvement in the early phases of BTK inhibitor therapy for CLL, building on previous clinical trials of chemoimmunotherapy.
